That approval was announced concurrent with the regulatory nod for Casgevy, a Vertex Pharmaceuticals gene ... Bluebird implemented a restructuring that cut 94 employees, representing about 25% ...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

The drugs show pharma at its best and its worst: drugs such as Vertex's Orkambi and Novartis ... EMA in September), both cut LDL cholesterol by more than 60% in hard-to-treat patients, but ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

25 analysts have shared their evaluations of Vertex Pharmaceuticals VRTX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...

Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals(NASDAQ ... for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

leveraging cutting-edge science to improve patient outcomes worldwide. Focusing on the healthcare sector, Vertex Pharmaceuticals has outpaced the VanEck Biotech ETF (BBH), which has gained 1% ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio's top stock picks. The American ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...